文献速递肾小球疾病

继发性IgA肾病与原发性IgA肾病具有相同的免疫特征

Secondary IgA Nephropathy Shares the Same Immune Features With Primary IgA Nephropathy.
PubMed 文献 · Kidney Int Rep · 2019-11-06

该研究检测了100例各种继发性IgA肾病患者血浆半乳糖缺陷型IgA1(Gd-IgA1)、IgA/IgG免疫复合物及肾小球Gd-IgA1沉积,并与健康对照、其他肾病患者及原发性IgA肾病比较。结果显示继发性IgA肾病血浆Gd-IgA1水平显著高于健康对照和其他肾病,但与原发性IgA肾病无差异,且肾小球均有Gd-IgA1沉积,提示二者发病机制相似。

要点

  • 继发性IgA肾病患者血浆Gd-IgA1水平显著高于健康对照和其他肾病患者。
  • 继发性与原发性IgA肾病在血浆Gd-IgA1及IgA1-IgG复合物水平上无差异。
  • 两种IgA肾病均存在肾小球系膜区Gd-IgA1沉积,提示共同发病机制。

核心结论

  • 继发性IgA肾病与原发性IgA肾病共享相似的Gd-IgA1导向的发病机制。

研究设计与样本

  • 研究纳入100例各种类型的继发性IgA肾病患者,检测血浆Gd-IgA1、IgA/IgG复合物及肾小球Gd-IgA1沉积。

主要发现

  • 继发性IgA肾病患者血浆Gd-IgA1中位数354.61 U/ml(IQR 323.93–395.57)高于健康对照中位数303.17 U/ml(IQR 282.24–337.92),P<0.001。
  • 继发性IgA肾病患者血浆Gd-IgA1中位数354.61 U/ml(IQR 323.93–395.57)高于其他肾病患者中位数314.61 U/ml(IQR 278.97–343.55),P<0.001。
  • 继发性与原发性IgA肾病血浆Gd-IgA1水平无差异:中位数378.54 U/ml(IQR 315.96–398.33) vs. 中位数378.54 U/ml(IQR 315.96–398.33),P=0.700。
  • 继发性与原发性IgA肾病IgA1-IgG复合物水平无差异:中位数18.76 U/ml(IQR 14.51–22.83) vs. 中位数19.11 U/ml(IQR 13.21–22.37),P=0.888。
  • 继发性和原发性IgA肾病均显示肾小球系膜区IgA1与Gd-IgA1共定位沉积。

临床怎么用

  • 继发性IgA肾病的评估可参考原发性IgA肾病的Gd-IgA1相关免疫指标。
  • 肾小球Gd-IgA1沉积检测有助于识别继发性IgA肾病的共同发病机制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Galactose-deficient IgA1 (Gd-IgA1) and related IgA/IgG immune complexes have been identified as the key drivers in the pathogenesis of IgA nephropathy (IgAN). However, their roles in the development of secondary IgAN are still unknown. METHODS: In this study, we measured the plasma Gd-IgA1 level, IgA/IgG complex, and Gd-IgA1 glomerular deposits in 100 patients with various kinds of secondary IgAN. Plasma Gd-IgA1 was measured using a lectin-based enzyme-linked immunosorbent assay, and Gd-IgA1 in glomerular deposits was examined by double immunofluorescent staining using its specific monoclonal antibody KM55. RESULTS: Patients with secondary IgAN presented with higher plasma Gd-IgA1 levels compared to healthy controls (median, 354.61 U/ml; interquartile range [IQR], 323.93, 395.57 U/ml vs. median, 303.17 U/ml; IQR, 282.24, 337.92 U/ml, P < 0.001) or patients with other kidney diseases (median, 314.61 U/ml; IQR, 278.97, 343.55 U/ml, P < 0.001). A similar trend was observed in plasma IgA/IgG immune complexes or IgA1. There were no differences between secondary and primary IgAN in plasma Gd-IgA1 levels (median, 378.54 U/ml; IQR, 315.96, 398.33 U/ml, P = 0.700) and IgA1-IgG complex levels (median, 18.76 U/ml; IQR, 14.51, 22.83 U/ml vs. median, 19.11 U/ml; IQR, 13.21, 22.37 U/ml, P = 0.888). Co-localized IgA1 and Gd-IgA1 of both secondary and primary IgAN indicated that they both share the feature of Gd-IgA1 deposits on the glomerular mesangium. CONCLUSION: Our study strongly suggests that secondary IgAN shares a similar galactose-deficient IgA1-oriented pathogenesis with primary IgAN.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Wang M, Lv J, Zhang X, et al. Secondary IgA Nephropathy Shares the Same Immune Features With Primary IgA Nephropathy. Kidney Int Rep. 2019. PMID: 32043030. doi:10.1016/j.ekir.2019.10.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。